Ikena Oncology Appoints Owen Hughes as Board Chair
Owen Hughes joins Ikena Board as independent director with operational and public company experience Ron Renaud steps down as he transitions into investment management role…
Browsing Tag
Nasdaq:IKNA
Ikena Oncology Provides Research & Development Update on IK-930 Program…
Clinical collaboration with AstraZeneca announced for the evaluation of osimertinib in combination with IK-930 for patients with EGFR-mutant lung cancers Company shares further detail on…
Ikena Oncology to Present Preclinical Findings on IK-930, a Novel TEAD Inhibitor at…
BOSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced…
Ikena Appoints Richard Wooster, Ph.D., to its Board of Directors
BOSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today…